PYC THERAPEUTICS LIMITED — Major Shareholding Notification 2012

Feb 1, 2012

==> picture [309 x 112] intentionally omitted <==

The Company Announcements Platform ASX Ltd Sydney NSW 2000 January 03, 2012

PHYLOGICA: NAOS ASSET MANAGEMENT INCREASES ITS SHAREHOLDING TO 11.5%

PERTH, AUSTRALIA: February 2, 2012 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that NAOS Asset Management has increased its shareholding to 51,492,121 shares (representing 11.5% of Phylogica’s issued share capital). This is an increase of 10,155,739 shares from NAOS’s previous reported holding in June 2011. The shares are held by Citicorp Nominees Pty Ltd.

NAOS Asset Management is an award winning boutique investment firm that specialises in investing in undervalued smaller companies through the NAOS Emerging Companies Long Short Equities Fund. The Fund was named the best performing hedge fund in the Asia Pacific Region for 2009 by Bloomberg and is a preeminent investment fund in the Australian Life Science industry.

-ends-

For further information, please contact:

Nick Woolf CFO & VP, Corporate Development Tel: +61 417 986 005 nwoolf@phylogica.com

Rudi Michelson Monsoon Communications Tel + 61 3 9620 3333

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia, and Oxford, UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company’s drug discovery platform is based on its proprietary Phylomer[®] libraries of natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer[®] libraries and proprietary screening technologies. Its current partners include Roche, MedImmune (AstraZeneca), Pfizer and Janssen Biotech (Johnson & Johnson).

PO Box 8207, Subiaco East, Western Australia 6008 Tel: +61 8 9384 3284 Fax: +61 8 9284 3801 www.phylogica.com ABN 48 098 391 961